Acromegaly Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Acromegaly Pipeline Drugs Market
Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea. Treatment includes surgery, dopamine agonists, and growth hormone antagonists.
The Acromegaly pipeline market research report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects.
Key Targets in the Acromegaly Pipeline Products Market
The key targets in the Acromegaly pipeline products market are Somatostatin Receptor, Somatostatin Receptor Type 2, Somatostatin Receptor Type 5, Growth Hormone Receptor, Somatostatin Receptor Type 4, Somatostatin Receptor Type 1, and Somatostatin Receptor Type 3. Somatostatin Receptor has the highest number of products.
Acromegaly Pipeline Products Market Analysis by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Acromegaly Pipeline Products Market
The key mechanisms of action in the Acromegaly pipeline products market are Somatostatin Receptor Agonist, Somatostatin Receptor Type 2 Agonist, Somatostatin Receptor Type 5 Agonist, Somatostatin Receptor Type 4 Agonist, Growth Hormone Receptor Antagonist, Growth Hormone Receptor Inhibitor, Somatostatin Receptor Antagonist, Somatostatin Receptor Type 1 Agonist, and Somatostatin Receptor Type 3 Agonist. Somatostatin Receptor Agonist leads this MoA segment.
Acromegaly Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Acromegaly Pipeline Products Market
The key routes of administration in the Acromegaly pipeline products market are oral, subcutaneous, sublingual, parenteral, and intramuscular. Subcutaneous leads this RoA segment.
Acromegaly Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Acromegaly Pipeline Products Market
The key molecule types in the Acromegaly pipeline products market are synthetic peptide, antisense oligonucleotide, small molecule, antisense RNAi oligonucleotide, fusion protein, peptide, and recombinant peptide. Synthetic peptide leads this segment.
Acromegaly Pipeline Products Market Analysis by Molecule Types
For more molecule-type insights, download a free report sample
Major Companies in the Acromegaly Pipeline Products Market
Some of the major companies in the Acromegaly pipeline products market are ASCIL Biopharm, Crinetics Pharmaceuticals Inc, Strongbridge Biopharma plc, Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, Camurus AB, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, and GeneScience Pharmaceuticals Co Ltd. ASCIL Biopharm have the highest number of products in the pipeline.
Acromegaly Pipeline Products Market Analysis by Companies
For more company insights, download a free report sample
Acromegaly Pipeline Products Market Report Overview
| Key Targets | Somatostatin Receptor, Somatostatin Receptor Type 2, Somatostatin Receptor Type 5, Growth Hormone Receptor, Somatostatin Receptor Type 4, Somatostatin Receptor Type 1, and Somatostatin Receptor Type 3 |
| Key Mechanisms of Action | Somatostatin Receptor Agonist, Somatostatin Receptor Type 2 Agonist, Somatostatin Receptor Type 5 Agonist, Somatostatin Receptor Type 4 Agonist, Somatostatin Receptor Antagonist, Somatostatin Receptor Type 1 Agonist, and Somatostatin Receptor Type 3 Agonist |
| Key Routes of Administration | Oral, Subcutaneous, Sublingual, Parenteral, and Intramuscular |
| Key Molecule Type | Synthetic Peptide, Antisense Oligonucleotide, Small Molecule, Antisense RNAi Oligonucleotide, Fusion Protein, Peptide, and Recombinant Peptide |
| Major Companies | Crinetics Pharmaceuticals Inc, Strongbridge Biopharma plc, Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, and GeneScience Pharmaceuticals Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Acromegaly (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acromegaly (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acromegaly (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Acromegaly (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acromegaly (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acromegaly (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amryt Pharma Plc
Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
ASCIL Biopharm
Camurus AB
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Debiopharm International SA
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
Genevant Sciences Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Rani Therapeutics LLC
Strongbridge Biopharma plc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Acromegaly products market?
The key targets in the Acromegaly pipeline products market are Somatostatin Receptor, Somatostatin Receptor Type 2, Somatostatin Receptor Type 5 , Growth Hormone Receptor, Somatostatin Receptor Type 4, Somatostatin Receptor Type 1, and Somatostatin Receptor Type 3.
-
What are the key mechanisms of action in the Acromegaly pipeline products market?
The key mechanisms of action in the Acromegaly pipeline products market are Somatostatin Receptor Agonist, Somatostatin Receptor Type 2 Agonist, Somatostatin Receptor Type 5 Agonist, Somatostatin Receptor Type 4 Agonist, Growth Hormone Receptor Antagonist, Growth Hormone Receptor Inhibitor, Somatostatin Receptor Antagonist, Somatostatin Receptor Type 1 Agonist, and Somatostatin Receptor Type 3 Agonist.
-
What are the key routes of administration in the Acromegaly pipeline products market?
The key routes of administration in the Acromegaly pipeline products market are oral, subcutaneous, sublingual, parenteral, and intramuscular.
-
What are the key molecule types in the Acromegaly pipeline products market?
The key molecule types in the Acromegaly pipeline products market are synthetic peptide, antisense oligonucleotide, small molecule, antisense RNAi oligonucleotide, fusion protein, peptide, and recombinant peptide.
-
Which are the major companies in the Acromegaly pipeline products market?
Some of the major companies in the Acromegaly pipeline products market are Crinetics Pharmaceuticals Inc, Strongbridge Biopharma plc, Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, Camurus AB, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, and GeneScience Pharmaceuticals Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Hormonal Disorders reports